Update on the management of prostate cancer with goserelin acetate: patient perspectives

References

• BrowerVWatchful waiting beats androgen deprivation therapy in early prostate cancerJ Natl Cancer Inst2008100211494149618957680
   PubMedGoogle Scholar
• Van LondenGisjsbertaJLevyMBody composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective studyCrit Rev Oncol Hematol200868217217718706829
   PubMed Web of Science ®Google Scholar
• KeatingNLO’MalleyAJSmithMRDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancerJ Clin Oncol200624274448445616983113
   PubMed Web of Science ®Google Scholar
• TsaiHKD’AmicoAVSadetskyAndrogen deprivation therapy for localized prostate cancer and the risk of cardiovascular moralityJ Natl Cancer Inst200799201516152417925537
   PubMedGoogle Scholar
• EfstathiouJAKyounghwaBShipleyWUCardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02Eur Eurol2008544816824
   Web of Science ®Google Scholar
• SmithMMalkowiczSChuFToremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III studyJ Clin Oncol200826111824182918398147
   PubMed Web of Science ®Google Scholar
• HelundPODamberJEHagermanIParenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Scand J Urol Nephrol200842322022918432528
   PubMedGoogle Scholar
• PollyEKChaseALSchultzLMIncreased risk of metabolic syndrome, diabetes mellitus and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancerPharmacotherapy200828121511152219025432
   PubMed Web of Science ®Google Scholar
• GalvaoDASpryNATaaffeDRChanges in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancerBJU Int20081021444718336606
   PubMed Web of Science ®Google Scholar
• PiirtolaMVahlbergTLopponenMFractures as predictors of excess mortality in the aged – a population-based study with a 12-year follow upEur J Epidemiol2008231174775518830674
   PubMed Web of Science ®Google Scholar
• FlaigTWGlodeLMManagement of the side effects of androgen deprivation therapy in men with prostate cancerExp Opin Pharmacother200891628292841
   PubMed Web of Science ®Google Scholar
• GreenspanSLNelsonJBTrumDLSkeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapyJ Clin Oncol200826274426443418802155
   PubMed Web of Science ®Google Scholar
• MichaelsonMDKaufmanDSLeeHRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerJ Clin Oncol20072591038104217369566
   PubMed Web of Science ®Google Scholar
• SmithMREsthamJGleasonDMRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol200316962008201212771706
   PubMed Web of Science ®Google Scholar
• WilsonLSTesoroRElkinEPCumulative cost pattern comparison of prostate cancer treatmentsCancer2007109351852717186528
   PubMed Web of Science ®Google Scholar
• NelsonCJLeeJSGamboaMCCognitive effects of hormone therapy in men with prostate cancer: a reviewCancer200811351097110618666210
   PubMed Web of Science ®Google Scholar
• DiBlasioCJHammettJMalcolmJBPrevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cacnerCan J Urol20081554249425618814813
   PubMed Web of Science ®Google Scholar
• LevyMEPereraSLNelsonGJPhysical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective studyUrology200871473573918279933
   PubMed Web of Science ®Google Scholar
• CurtisKKAdamTJChenSAnaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart reviewAging Male200811415716118937151
   PubMed Web of Science ®Google Scholar
• BongGWClarkeHSHancockWCSerum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancerUrology20087161177118018279929
   PubMed Web of Science ®Google Scholar
• HeidenreichAGunnarABollaMEAU guidelines on prostate cancerEur Urol2008531688017920184
   PubMed Web of Science ®Google Scholar
• IversenPJohanssonJELoddingPBicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 yearsScand J Urol Nephrol200640644145217130095
   PubMed Web of Science ®Google Scholar
• McLeodDGIversenPSeeWABicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU Int200697224725416430622
   PubMed Web of Science ®Google Scholar
• PilepichMVWinterKLawtonCAAndrogen suppression adjuvant to definitive radiotherapy in carcinoma – long-term results of phase III RTOG 85–31Int J Radiat Oncol Biol Phys20025351097110512128107
   PubMed Web of Science ®Google Scholar
• Jereczek-FossaBAVavassoriAFodorCDose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patientsInt J Radiat Oncol Biol Phys200871378479418191332
   PubMed Web of Science ®Google Scholar
• MendenhallWMHendersonRHMendenhallNPDefinitive radiotherapy for prostate cancerAm J Clin Oncol200831549650318838889
   PubMed Web of Science ®Google Scholar
• BeasleyMWilliamsSGPicklesTExpanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapyRadiat Oncol20083818423030
   PubMed Web of Science ®Google Scholar
• Lu-YaoGLAlbertsenPCMooreDFSurvival following primary androgen deprivation therapy among men with localized prostate cancerJAMA2008300217318118612114
   PubMed Web of Science ®Google Scholar
• StuderUEColletteLWhelanPUsing PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)Eur Urol200852594194918191322
   PubMed Web of Science ®Google Scholar
• SteineckGHelgesenFAdolfssonJQuality of life after radical prostatectomy or watchful waitingN Engl J Med20023471179079612226149
   PubMed Web of Science ®Google Scholar
• ErcoleBMariettiSRFineJOutcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen eraJ Urol200818041336133918707696
   PubMed Web of Science ®Google Scholar
• AndrioleGLGrubbRLBuysSSMortality results from a randomized prostate-cancer screening trialN Engl J Med2009360131310131919297565
   PubMed Web of Science ®Google Scholar
• SchroderFHHugossonJRoobolMJScreening and prostate-cancer mortality in a randomized European studyN Engl J Med2009360131320132819297566
   PubMed Web of Science ®Google Scholar
• SimmonsMNStephensonAJKleinEANatural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapyEur Urol200751511758417240528
   PubMed Web of Science ®Google Scholar
• SharifiNGulleyJDahutWLAndrogen deprivation therapy for prostate cancerJAMA2005294223824416014598
   PubMed Web of Science ®Google Scholar
• SotoDEAndrigeRRPanCCIn patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free intervalInt J Radiat Oncol Biol Phys20087151295130118472361
   PubMed Web of Science ®Google Scholar
• PalmaDTyldesleySPicklesTPretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapyCancer200811291941194818338814
   PubMed Web of Science ®Google Scholar
• WilliamsSGBuyyounouskiMPicklesTKPercentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performanceInt J Rad Oncol Bio Phys200870411691175
   Web of Science ®Google Scholar
• D’AmicoAVRenshawAASussmanBPretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapyJAMA20072944440447
   Web of Science ®Google Scholar
• D’AmbrosioDJRuthKHorwitzEMHow can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?Int J Radiat Oncol Biol Phys20087051487149118164854
   PubMed Web of Science ®Google Scholar
• RodriguesNAChenMHCatalonaWJPredictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancerCancer2006107351452016795068
   PubMed Web of Science ®Google Scholar
• OkegawaTNutaharaKHigashiharaEImmunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naïve metastatic prostate cancerJ Urol200818041342134718707699
   PubMed Web of Science ®Google Scholar
• D’AmicoAVLoffredoMRenshawAASix-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen levelJ Clin Oncol200624254190419516943536
   PubMed Web of Science ®Google Scholar
• ZelefskyMJYamadaYFuksZLong-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomesInt J Radiat Oncol Biol Phys20087141028103318280056
   PubMed Web of Science ®Google Scholar
• DenhamJWSteiglerAWilcoxCTime to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality; evidence from the TROG 96.01 randomized controlled trialLancet Oncol20089111058106818929505
   PubMed Web of Science ®Google Scholar
• HanksGEPajakTFPorterAPhase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02J Clin Oncol200321213972397814581419
   PubMed Web of Science ®Google Scholar
• BollaMColletteLBlankLLong-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trialLancet20029327 360:10310612126818
   PubMed Web of Science ®Google Scholar
• ZapateroAGarcia-VicenteFSevillanoDIs hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer?Urology20087251130113418400265
   PubMed Web of Science ®Google Scholar
• MessingEManolaJYaoJImmediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyLancet Oncol20067647247916750497
   PubMed Web of Science ®Google Scholar
• PetitJHGluckCKigerWSBicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidityUrol Oncol200826437237718367113
   PubMed Web of Science ®Google Scholar
• GhafarMAJohnsonCEDe La TailleASalvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experienceJ Urol200116641333133711547068
   PubMed Web of Science ®Google Scholar
• Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators GroupBr J Urol19977922352469052476
   PubMedGoogle Scholar
• StangelbergerAShallyAVDjavanBNew treatment approaches for prostate cancer based on peptide analoguesEur Urol200853589090018201818
   PubMed Web of Science ®Google Scholar
• KexinXShimelisHLinnDERegulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitinationCancer Cell200915427028219345326
   PubMed Web of Science ®Google Scholar
• XuKShimelisHLinnDERegulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitinationCancer Cell200915424524719345321
   PubMed Web of Science ®Google Scholar
• ShahSKTrumpDLSartorOPhase II study of dutasteride for recurrent prostate cancer during androgen deprivation therapyJ Urol2009181262162619091347
   PubMed Web of Science ®Google Scholar
• SerdaREBisoffiMThompsonTA1alpha, 25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cellsProstate200868777378318247401
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU Int2008102111531153819035858
   PubMed Web of Science ®Google Scholar
• Van PoppelHTombalBde la RosetteJJDegareliz: a novel gonadotropin-releasing hormone (GnRh) receptor blocker – results from a 1-yr, multicentre, randomized, phase 2 dosage-finding study in the treatment of prostate cancerEur Urol200854480581318538469
   PubMed Web of Science ®Google Scholar